



General description

| | |
|----------------------------|--|
| INN | Amikacin |
| ATC codes | J01GB06 |
| Medicine type | Chemical agent |
| Antibiotic groups | A ACCESS |
| EML status history | First added in 1999 (TRS 895) for Multi-drug resistant Mycobacterium tuberculosis Added in 2017 (TRS 1006) for Sepsis without septic shock Added in 2017 (TRS 1006) for Neutropenia Added in 2017 (TRS 1006) for Acute pyelonephritis Added in 2017 (TRS 1006) for Inflammatory and other diseases of prostate Changed in 2021 (TRS 1035) for Infectious blepharitis Changed in 2021 (TRS 1035) for Other specified conjunctivitis |
| Therapeutic equivalent for | gentamicin for Infectious blepharitis gentamicin for Other specified conjunctivitis |
| Wikipedia | Amikacin  |
| DrugBank | Amikacin  |

Recommendations

Section Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neutropenia (high-risk)

co-prescribed with [cefotaxime](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [cefotaxime](#)

Acute pyelonephritis (severe)

co-prescribed with [ceftriaxone](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [ceftriaxone](#)

Acute pyelonephritis (severe)

Second choice

co-prescribed with [cloxacillin](#)

Sepsis without septic shock

Section Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Multi-drug resistant Mycobacterium tuberculosis

